Background: neovascularization is a new measure of treatment for ischemic heart disease and occlusive atherosclerosis.
2
本实验从三方面研究冠脉搭桥与骨髓干细胞动员相结合治疗缺血性心脏病的可行性。
The feasibility of combined coronary artery bypass graft and bone marrow stem cell mobilization for ischemia heart disease treatment was studied in three parts.
3
因此，丙二酸辅酶a脱羧酶(MCD)抑制剂代表着一个令人振奋的治疗缺血性心脏病的新靶点。
Hence, inhibition of MCD represents an exciting new target for the treatment of ischemic heart disease.
点击反馈